ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

587
Analysis
Health Care • China
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
•30 Nov 2018 05:53

G20 Game of Roulette:  Where Will Trump-Xi Ball Land? + 2018 Holiday Season Conviction Shorts

From conversations with investors, we believe that the market strongly expects a “positive” outcome whereby the US agrees to freeze the trade...

Logo
520 Views
Share
bearish•WuXi AppTec
•20 Nov 2018 20:34

WuXi AppTech IPO Trading Update: What’s up with the Poor Cash Conversion?

WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
1k Views
Share
bullish•WuXi AppTec
•19 Nov 2018 06:57

WuXi AppTech IPO Preview: Pharmed Out

WuXi AppTec Co Ltd (603259 CH) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
1.3k Views
Share
•28 Jun 2018 05:01

Updated Proxy Filed and Q4 Results Released

iKang Healthcare Group (ADR) (KANG US) simultaneously reported its March quarter results and filed the updated proxy for its privatization at...

Share
•26 Jun 2018 15:55

Trade Risks Start to Impact, as China Biotech Ambitions Grow…

Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...

Logo
257 Views
Share
x